Clinical Trial Update: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 dose-escalation trial evaluating glofitamab as a single agent and in combination with obinutuzumab after a fixed pre-treatment dose of obinutuzumab …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: RECRUITING